BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34486197)

  • 1. HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma.
    Zhang ZS; Yang RH; Yao X; Cheng YY; Shi HX; Yao CY; Gao ZX; Qi DF; Zhang WK; Dou YY; Guo J; Hu MW; Zhao H; Fang D
    Cell Biol Int; 2021 Dec; 45(12):2521-2533. PubMed ID: 34486197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
    Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
    Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
    Steinway SN; Dang H; You H; Rountree CB; Ding W
    PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression.
    Balan M; Mier y Teran E; Waaga-Gasser AM; Gasser M; Choueiri TK; Freeman G; Pal S
    J Biol Chem; 2015 Mar; 290(13):8110-20. PubMed ID: 25645920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-neoplastic Effect of Ginkgolide C through Modulating c-Met Phosphorylation in Hepatocellular Carcinoma Cells.
    Yang MH; Baek SH; Um JY; Ahn KS
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1.
    Li S; Ji J; Zhang Z; Peng Q; Hao L; Guo Y; Zhou W; Cui Q; Shi X
    Mol Cell Biochem; 2020 Dec; 475(1-2):79-91. PubMed ID: 32761300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells.
    Usatyuk PV; Fu P; Mohan V; Epshtein Y; Jacobson JR; Gomez-Cambronero J; Wary KK; Bindokas V; Dudek SM; Salgia R; Garcia JG; Natarajan V
    J Biol Chem; 2014 May; 289(19):13476-91. PubMed ID: 24634221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.
    Wu L; Cai S; Deng Y; Zhang Z; Zhou X; Su Y; Xu D
    Int Immunopharmacol; 2021 May; 94():107443. PubMed ID: 33581579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
    Dong G; Chen Z; Li ZY; Yeh NT; Bancroft CC; Van Waes C
    Cancer Res; 2001 Aug; 61(15):5911-8. PubMed ID: 11479233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
    Huang X; Gan G; Wang X; Xu T; Xie W
    Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte growth factor protects hepatoblastoma cells from chemotherapy-induced apoptosis by AKT activation.
    Grotegut S; Kappler R; Tarimoradi S; Lehembre F; Christofori G; Von Schweinitz D
    Int J Oncol; 2010 May; 36(5):1261-7. PubMed ID: 20372801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
    Yuan S; Gong Y; Chen R; Du J; Zhang H; Chen T
    Biomed Pharmacother; 2020 Dec; 132():110867. PubMed ID: 33075668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/β-catenin, and PI3K/Akt/mTOR signaling pathways.
    Yassin NYS; AbouZid SF; El-Kalaawy AM; Ali TM; Almehmadi MM; Ahmed OM
    Biomed Pharmacother; 2022 Jan; 145():112409. PubMed ID: 34781148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway.
    Zhao M; Wang Y; Liu Y; Zhang W; Liu Y; Yang X; Cao Y; Wang S
    Cancer Biol Ther; 2019; 20(12):1430-1442. PubMed ID: 31441380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.
    Wu M; Xia X; Hu J; Fowlkes NW; Li S
    Nat Commun; 2021 Jun; 12(1):3500. PubMed ID: 34108491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SRSF10 facilitates HCC growth and metastasis by suppressing CD8
    Luo X; Zhang Z; Li S; Wang Y; Sun M; Hu D; Jiang J; Wang Y; Ji X; Chen X; Zhang B; Liang H; Li Y; Liu B; Xu X; Wang S; Xu S; Nie Y; Wu K; Fan D; Liu D; Huang W; Xia L
    Int Immunopharmacol; 2024 Jan; 127():111376. PubMed ID: 38113691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.